Skip to main content
OpenTrials
Completed

NCT Number: NCT04838756

Mammography Screening With Artificial Intelligence (MASAI)

The purpose of this randomized controlled trial is to assess whether AI can improve the efficacy of mammography screening, by adapting single and double reading based on AI derived cancer-risk scores and to use AI as a decision support in the screen reading, compared with conventional mammography screening (double reading without AI).

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–74 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mammography Unit, Unilabs/Skane University Hospital

Malmö, Skåne County, 20550, Sweden

About this study

European guidelines recommend that mammography exams in breast cancer screening are read by two breast radiologists to ensure a high sensitivity. Double reading is, however, resource demanding and still results in missed cancers. Computer-aided detection based on AI has been shown to have similar accuracy as an average breast radiologist. AI can be used as decision support by highlighting suspicious findings in the image as well as a means to triage screen exams according to risk of malignancy.

Eligible women will be randomized (1:1) to the intervention (AI-integrated mammography screening) or control arm (conventional mammography screening). In the intervention arm, exams will be analysed with AI and triaged into two groups based on risk of malignancy. Low risk exams will be single read and high risk exams will be double read. The high risk group will contain appx. 10% of the screening population. Within the high-risk group, exams with the highest 1% risk will by default be recalled by the readers with the exception of obvious false positives. AI risk scores and Computer-Aided Detection (CAD)-marks of suspicious calcifications and masses are provided to the reader(s). In the control arm, screen exams are double read without AI (standard of care). Considering the interplay of number of interval cancers and workload, the study will be considered successful if the interval-cancer rate in the intervention arm is not more than 20% larger than in the control arm. If the interval-cancer rate is statistically and clinically significantly lower in the intervention arm than in the control arm, AI-integrated mammography screening will be considered superior to conventional mammography screening.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women eligible for population-based mammography screening.

Exclusion criteria

None.

Treatment and study plan

AI screening modality

Other

Screen exam will be analysed with an AI system (Transpara, ScreenPoint, Nijmegen, The Netherlands) that assigns exams with a cancer-risk score from 1 to 10, as well as presenting CAD-marks at suspicious findings. Exams with risk score 1-9 will be single read and exam with score 10 will be double read. Risk scores and CAD-marks are provided to the reader(s). The reader(s) will decide whether to recall the woman for work-up or not (as per standard of care). In addition, exams with the highest 1% risk will by default be recalled with the exception of obvious false positives.

Conventional screening modality

Other

Screen exams will be read by two radiologists without the support of AI.

Primary outcomes

  1. Interval-cancer rate

    Time frame: 43 months

    Women with interval cancer per 1000 screens

Secondary outcomes

  1. Cancer-detection rate

    Time frame: 15 months

    Women with screen-detected cancer per 1000 screens

  2. Recall rate

    Time frame: 15 months

    Number of recalls per 1000 screens

  3. False-positive rate

    Time frame: 15 months

    Women with false positive per 1000 screens

  4. Positive Predictive Value-1

    Time frame: 15 months

    Women with cancer for all recalls

  5. Sensitivity and specificity

    Time frame: 43 months

    True and false-positive rate

  6. Cancer detection per cancer type

    Time frame: 19 months

    Screen detection of cancer in relation to cancer type, size and stage

  7. Tumour biology of interval cancers

    Time frame: 43 months

    Characterization of interval cancers per type, size and stage

  8. Screen-reading workload

    Time frame: 19 months

    Number of screen-readings and number of consensus meetings

  9. Incremental cost-effectiveness ratio

    Time frame: 43 months

    The incremental cost-effectiveness ratio for AI-integrated mammography screening versus standard of care

Sponsors and collaborators

Lead sponsor

Region Skane

Other

Collaborators

  • Norwegian Institute of Public Health
  • Unilabs

Registry information

Official study title

A Randomized, Single-blinded, Controlled Trial on the Efficacy of Mammography Screening With Artificial Intelligence - the MASAI Study

Acronym: MASAI

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Apr 9, 2021
Registry last updated
Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.